Freya Pharma Solutions Announces Launch of Phase 2 Clinical Dose-Response Study Testing its Lybrido Concept Targeting Female Sexual Dysfunction
Freya Pharma Solutions recently announced the initation of a Phase 2 clinical study evaluating its Lybrido concept. The study will investigate two dose-combinations of testosterone…
Microbiotica Announces Completion of Recruitment in its Phase 1b Trial of a Precision Microbiome Medicine in Ulcerative Colitis Patients
Microbiotica recently announced patient recruitment is complete in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. This international trial has…
Medicus Pharma Announces MoU With Helix Nanotechnologies to Develop Thermostable Infectious Disease Vaccines
Medicus Pharma Ltd. and Helix Nanotechnologies Inc. recently announced they have entered into a non-binding memorandum of understanding (MoU) in respect of their shared mutual interest…
HilleVax Enters Into Definitive Agreement to be Acquired by XOMA Royalty
HilleVax, Inc and XOMA Royalty Corporation recently announced they have entered into a definitive merger agreement, whereby XOMA Royalty will acquire all of the issued…
Atavistik Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ATV-1601 in Patients With AKT1 E17K-Mutant Solid Tumors
Atavistik Bio recently announced the dosing of the first patient in its Phase 1 study of ATV-1601 in adults with AKT1 E17K-mutant solid tumors. ATV-1601…
XOMA Royalty Enters Agreement to Acquire LAVA Therapeutics
XOMA Royalty Corporation and LAVA Therapeutics N.V. recently announced they have entered a definitive share purchase agreement whereby XOMA Royalty will acquire LAVA for (i)…
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety & Depression
Artelo Biosciences, Inc. recently announced that it has received written scientific advice from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on the nonclinical development…
Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation
Silexion Therapeutics Corp recently announced groundbreaking new preclinical data revealing unprecedented inhibition rates of up to 97% in pancreatic cancer cells and almost 90% in…
Symbiosis Reaches Major Milestone With Injectable Drug Product
Symbiosis Pharmaceutical Services recently announced the successful completion of its 1,000th sterile drug product batch, marking a significant milestone in its mission to accelerate access…
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate
Palisade Bio, Inc. recently announced the China National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, the company’s novel,…
VedTechBio Unveils Next-Gen Drug Discovery AI; Partners With AlphaMeld in Multi-Therapy Collaboration
VedTechBio Research Pvt. Ltd. recently announced major enhancements to its RxAgentAI platform, cutting drug discovery timelines in half, alongside a strategic collaboration with AlphaMeld Corporation…
Oragenics Selects Southern Star Research as CRO for ONP-002 Phase 2a Trial
Oragenics, Inc. recently announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase 2a clinical trial of ONP-002,…
Pancreatic Cancer Phase 2a Study With Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
Can-Fite BioPharma Ltd. recently announced that it achieved the over 50% enrollment milestone in its Phase 2a trial of Namodenoson for pancreatic cancer. The Phase…
Incannex Reports Positive Topline Results From RePOSA Phase 2 Trial of IHL-42X
Incannex Healthcare Inc. recently announced positive topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for obstructive sleep…
FDA Provides Trethera Clearance to Initiate Clinical Trial in Healthy Volunteers to Study Food Effect & Biomarkers
Trethera Corporation recently announced the US FDA has cleared a clinical trial evaluating its novel drug, TRE-515, in healthy volunteers. TRE-515, a clinical-stage drug in…
Merck Advances Neuroscience Pipeline With Novel Therapies in Phase 2 Studies for Treatment of Alzheimer’s Disease
Merck, known as MSD outside of the US and Canada, a premier research-intensive biopharmaceutical company, is initiating two Phase 2 clinical studies for MK-2214 and…
Ofichem Expands Drug Substance Capabilities With Acquisition of Meribel Pharma Solutions’ Uppsala Site in Sweden
Ofichem recently announced the acquisition of Meribel Pharma Solutions’ site in Uppsala, Sweden. This strategic step enhances Ofichem’s ability to support early phase, IP-driven drug…
Centauri Therapeutics Receives an Additional $5.1 Million From CARB-X to Progress ABX-01 Lead Compound to First-in-Human Clinical Trials
Centauri Therapeutics Limited recently announced CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1 million in funding for the development of their lead…
BriaPro Therapeutics Files Patent Application for Immuno-Oncology Platform With Novel Multitargeting Agents
BriaCell Therapeutics Corp. and its majority owned subsidiary, BriaPro Therapeutics Corp., recently announce BriaPro is developing novel multivalent agents for cancer treatment. BriaPro has filed…
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease
Therini Bio, Inc. recently announced the first patient has been dosed in a Phase 1b trial evaluating THN391 for the treatment of Alzheimer's disease (AD).…
